Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571025 · ClinicalTrials.gov registry record · NA
Risk Evaluation and Education for Alzheimer's Disease
A NA study, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- NA
- Development phase
- 301
- Enrollment target
NCT00571025: Completed NA study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00571025 is a NA study that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 301 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00571025, a NA study, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- NA
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.
Interventions
- BEHAVIORAL APOE Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2000-08 |
| Est. Completion | 2004-04 |
| Phase | NA |
What the finished NCT00571025 record still lists
NCT00571025 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which APOE Disclosure is the first listed.
NCT00571025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00571025 about?
NCT00571025 is a clinical study titled "Risk Evaluation and Education for Alzheimer's Disease". The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.
What is the current status of trial NCT00571025?
This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2000-08. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00571025?
The interventions under investigation include: APOE Disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT00571025?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00571025's enrollment target sits among peer trials
301 330th of 2000 higher than 1,671 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia